Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Guangzhou
Clinical trial register · China

Clinical Trials in Guangzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 08 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Beijing 5576 Shanghai 3879 Guangzhou 3345 Hangzhou 1819 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Sun Yat-sen University444 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University184 Nanfang Hospital, Southern Medical University138 AstraZeneca136 Guangdong Provincial People's Hospital82
Site location
Beijing5576 Shanghai3879 Guangzhou3345 Hangzhou1819 Wuhan1343
All 625 locations
Target enrolment
to

Trials with a site in Guangzhou

3345 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Shanghai Hongdian Medical CO., LTD
Not applicable
180
Chongqing, Xiamen, Lanzhou, Guangzhou, Guiyang, Harbin, Zhengzhou, Zhenzhou
2023-03-31
Active, closed
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
1,946
Beijing, Guangzhou, Suining
2023-03-30
Active, closed
Janssen Research & Development, LLC
Phase 3
614
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2023-03-29
Active, closed
Janssen Research & Development, LLC
Phase 3
1,135
Beijing, Changchun, Changsha, Chengdu, Chongqing, Deyang, Guangzhou, Hangzhou
2023-03-23
Recruiting
CEUS Improves the Diagnostic Performance of SRSS of Thyroid Carcinoma
NCT06146764Thyroid Nodule, Thyroid Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
800
Guangzhou
2023-03-18
Active, closed
Merck Sharp & Dohme LLC
Phase 3
300
Beijing, Chongqing, Guangzhou, Guiyang, Haikou, Zhengzhou, Wuhan, Changsha
2023-03-16
Recruiting
Teligene US
Phase 2
60
Beijing, Chongqing, Fuzhou, Guangzhou, Harbin, Zhengzhou, Wuhan, Changsha
2023-03-16
Active, closed
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 1/2
725
Beijing, Changsha, Fuzhou, Guangzhou, Hangzhou, Ha’erbin, Hefei, Jinan
2023-03-15
Active, closed
Guangdong Provincial People's Hospital
Phase 2
48
Beijin, Guangzhou, Changsha
2023-03-15
Active, closed
AbbVie
Phase 3
520
Bengbu, Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan
2023-03-15
Recruiting
Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab
NCT05760612Early-stage Breast Cancer, HER2-positive Breast Cancer, Adjuvant Treatment After Trastuzumab, RCB Classification 1-2
DrugTrastuzumab and Pertuzumab
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3
300
Guangzhou
2023-03-14
Recruiting
Ascentage Pharma Group Inc.
Phase 1
105
Guangzhou
2023-03-13
Recruiting
Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers
NCT05779917Pancreas Cancer, CAR-T Cell Therapy, Mesothelin, Solid Tumor, Adult
Second Affiliated Hospital of Guangzhou Medical University
Phase 1
30
Guangzhou
2023-03-10
Active, closed
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
NCT05739383Primary Prevention of Atherosclerotic Cardiovascular Disease
DrugInclisiran
Novartis Pharmaceuticals
Phase 3
14,012
Guangzhou, Nanning, Cangzhou, Shijiazhuang, Tangshan, Xingtai, Daqing, Harbin
2023-03-09
Active, closed
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
219
Fuzhou, Guangzhou, Harbin, Zhengzhou, Changsha, Nanjing, Shenyang, Xi'an
2023-03-09
Recruiting
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1
191
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Zhengzhou
2023-03-09
Recruiting
Sun Yat-sen University
Phase 2
55
Guangzhou
2023-03-09
Recruiting
OH2 Injection in Melanoma
NCT05868707Melanoma
DrugOH2
Binhui Biopharmaceutical Co., Ltd.
Phase 3
340
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Haikou, Shijiazhuang, Harbin
2023-03-08
Recruiting
Evaluation of COVID-19 Immune Barrier and Reinfection Risk
NCT05774093COVID-19 Infection, Immunization; Infection
Sun Yat-sen University
Observational
300
Guangzhou
2023-03-06
Active, closed
Pfizer
Phase 3
624
Hefei, Beijing, Fuzhou Fujian, Foshan, Guangzhou, Nanning, Harbin, Luoyang
2023-03-03
Active, closed
Novartis Pharmaceuticals
Phase 3
436
Guangzhou, Shantou, Haikou, Zhuzhou, Nanjing, Suzhou, Nanchang, Pingxiang
2023-03-02
Recruiting
The Eye Hospital of Wenzhou Medical University
Observational
1,000,000
Guangzhou, Wenzhou
2023-03-01
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
100
Guangzhou
2023-03-01
Recruiting
AI-Assisted System for Accurate Diagnosis and Prognosis of Breast Phyllodes Tumors
NCT06286267Phyllodes Breast Tumor, Artificial Intelligence, Multiomics, Prognostic Cancer Model
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
4,000
Guangzhou
2023-03-01
Recruiting
Sun Yat-sen University
Phase 3
176
Hefei, Foshan, Guangzhou, Nanning, Harbin, Zhengzhou, Nanchang, Shanghai
2023-03-01
Recruiting
Prospective Collection of Therapeutic Efficacy and Safety Data in Patients with Unresectable Hepatocellular Carcinoma
NCT06788353Transarterial Chemoembolization, Systemic Therapy, Unresectable Hepatocellular Carcinoma
Sun Yat-sen University
Observational
500
Guangzhou
2023-03-01
Recruiting
Single-cell Multiomics and Spatiotemporal Omics Analyze the Mechanism of Liver Degenerative Disease
NCT07265544Liver Neoplasm, HBV Infection, Non-alcoholic Fatty Liver Disease NAFLD, Liver Fibrosis
Nanfang Hospital, Southern Medical University
Observational
240
Guangzhou
2023-03-01
Not yet open
Sun Yat-sen University
Phase 3
136
Guangzhou
2023-03
Active, closed
Taizhou Hanzhong biomedical co. LTD
Phase 3
190
Bengbu, Fuyang, Hefei, Beijing, Fuzhou, Lanzhou, Foshan, Guangzhou
2023-02-28
Recruiting
The Efficacy of Vosevi in Treating DAA-experienced Patients
NCT06180590Chronic Hepatitis C, Medication Reaction
The Third Affiliated Hospital of Guangzhou Medical University
Observational
200
Guangzhou
2023-02-28
Recruiting
Ascentage Pharma Group Inc.
Phase 1/2
100
Guangzhou, Wuhan, Tianjin
2023-02-28
Recruiting
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1
146
Guangzhou, Changchun, Chengdu
2023-02-23
Recruiting
Shanghai AbelZeta Ltd.
Phase 1/2
112
Beijing, Chongqing, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Shanghai
2023-02-22
Recruiting
Xijing Hospital of Digestive Diseases
Phase 3
150
Lanzhou, Guangzhou, Nanjing, Shenyang, Xi'an, Chengdu, Tianjin
2023-02-22
Active, closed
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 2
62
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Meizhou
2023-02-21
Active, closed
A Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHL
NCT05627856NK/T Cell Lymphoma, Vascular Immunomother T Cell Lymphoma, Non-Hodgkin Lymphoma
DrugGNC-038
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
4
Guangzhou
2023-02-21
Recruiting
ctDNA-guided Adjuvant Chemotherapy in Liver Metastasis of Colorectal Cancer
NCT05815082Colorectal Cancer, Liver Metastases, Circulating Tumor Cell, Chemotherapy Effect
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3
490
Guangzhou
2023-02-20
Recruiting
Postoperation Maintenance Therapy for Resectable Liver Metastases of Colorectal Cancer Guided by ctDNA
NCT05797077Colorectal Cancer, Liver Metastases, Circulating Tumor Cell, Cancer, Therapy-Related
DrugCapecitabine
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3
346
Guangzhou
2023-02-20
Recruiting
The Proactive Ophthalmic Examination Cohort
NCT05851287Vision Impairment, Eye Diseases
Zhongshan Ophthalmic Center, Sun Yat-sen University
Observational
5,000
Guangzhou
2023-02-20
Recruiting
Xijing Hospital of Digestive Diseases
Phase 2/3
104
Beijing, Guangzhou, Zhengzhou, Changsha, Nanjing, Shenyang, Xi'an, Yan’an
2023-02-17
Recruiting
Submental Flap for the Reconstruction of Hypopharyngectomy
NCT06161779Head and Neck Cancers - Hypopharyngeal
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
40
Guangzhou
2023-02-16
Active, closed
AstraZeneca
Phase 3
214
Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan
2023-02-15
Recruiting
Sun Yat-sen University
Observational
30
Guangzhou
2023-02-15
Active, closed
Qilu Pharmaceutical Co., Ltd.
Phase 3
606
Guangzhou
2023-02-15
Active, closed
Merck Sharp & Dohme LLC
Phase 3
377
Hefei, Beijing, Wanzhou, Fuzhou, Guangzhou, Jiangmen, Shenzhen, Wuhan
2023-02-14
Active, closed
A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A
NCT05685238Haemophilia A, Haemophilia A With Inhibitors
Novo Nordisk A/S
Phase 3
451
Beijing, Guangzhou, Wuhan, Changsha, Jinan, Chengdu, Tianjin, Huzhou
2023-02-13
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
7
Beijing, Guangzhou, Zhengzhou
2023-02-10
Active, closed
Takeda
Phase 2
52
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei
2023-02-10
Recruiting
Zhejiang ACEA Pharmaceutical Co. Ltd.
Phase 1/2
84
Beijing, Guangzhou, Hangzhou
2023-02-09
Active, closed
AstraZeneca
Phase 2
51
Beijing, Chengdu, Fuzhou, Guangzhou, Kunming, Ningbo, Shijiazhuang, Suzhou
2023-02-09
Active, closed
Genmab
Phase 3
900
Beijing, Fuzhou, Xiamen, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan
2023-02-08
Recruiting
Juventas Cell Therapy Ltd.
Phase 1/2
47
Hefei, Chongqing, Guangzhou, Wuhan, Nanjing, Xuzhou, Nanchang, Tianjin
2023-02-07
Active, closed
Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer
NCT05426005Colorectal Cancer Stage IV, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H)
DrugCadonilimab
Sun Yat-sen University
Phase 1/2
28
Guangzhou
2023-02-07
Active, closed
Merck Sharp & Dohme LLC
Phase 3
614
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Harbin
2023-02-06
Active, closed
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
24
Guangzhou
2023-02-05
Active, closed
Assessment of DOT Spectacles in Chinese Children
NCT05562622Juvenile Myopia, Myopia
SightGlass Vision, Inc.
Not applicable
195
Changsha, Chengdu, Guangzhou, Shanghai, Tianjin
2023-02-05
Recruiting
A Real-world Study of Nitric Oxide Generator and Delivery System
NCT05703191Pulmonary Hypertension of Newborn
Novlead Inc.
Observational
10
Guangzhou
2023-02-03
Active, closed
Novartis Pharmaceuticals
Phase 3
226
Beijing, Guangzhou, Shenzhen, Shijiazhuang, Luoyang, Zhengzhou, Changzhou, Nanchang
2023-02-03
Active, closed
Novartis Pharmaceuticals
Phase 3
152
Guangzhou, Wuhan, Binzhou, Hangzhou, Beijing, Jinan, Tianjin
2023-02-02
Active, closed
Sanofi
Phase 3
91
Beijing, Guangzhou, Jinan
2023-02-01
Recruiting
Sun Yat-sen University
Phase 2
36
Guangzhou
2023-02-01
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
62
Guangzhou
2023-01-31
Active, closed
BeiGene
Phase 1/2
113
Hefei, Beijing, Fuzhou, Quanzhou, Xiamen, Guangzhou, Shantou, Zhengzhou
2023-01-29
Active, closed
Shenzhen TargetRx Co., Ltd.
Phase 2
164
Guangzhou
2023-01-18
Active, closed
Klus Pharma Inc.
Phase 2
240
Guangzhou, Nanning, Wuhan, Changsha, Changchun, Dalian, Weifang, Xi’an
2023-01-17
Recruiting
Guangzhou Sinogen Pharmaceutical Co., Ltd
Phase 1/2
70
Guangzhou, Harbin, Changsha, Shanghai, Chengdu
2023-01-16
Active, closed
ABTECT - Maintenance
NCT05535946Ulcerative Colitis
DrugObefazimod
Abivax S.A.
Phase 3
1,116
Wuhu, Beijing, Fuzhou, Guangzhou, Luoyang, Zhengzhou, Wuhan, Shenyang
2023-01-16
Active, closed
Bristol-Myers Squibb
Phase 3
516
Bengbu, Beijing, Xiamen, Guangzhou, Shenzhen, Baoding, Luoyang, Zhengzhou
2023-01-12
Recruiting
LaNova Medicines Limited
Phase 1/2
139
Guangzhou, Wuhan, Linyi, Beijing, Shanghai
2023-01-11
Active, closed
Bristol-Myers Squibb
Phase 3
606
Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Nantong
2023-01-10
Active, closed
BeiGene
Phase 1/2
113
Beijing, Fuzhou, Lanzhou, Guangzhou, Nanning, Zhengzhou, Wuhan, Changsha
2023-01-09
Active, closed
Adult Spinal Muscular Atrophy (SMA) China Registry
NCT05618379Muscular Atrophy, Spinal
Biogen
Observational
200
Beijing, Fuzhou, Guangzhou, Shenzhen, Shijiazhuang, Changsha, Suzhou, Nanchang
2023-01-06
Recruiting
Mycophenolate Mofetil in Gastrointestinal Henoch-Schonlein Purpura
NCT05951517Henoch-Schönlein Purpura, Gastrointestinal Injury, Mycophenolate Mofetil
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
24
Guangzhou
2023-01-01
Recruiting
Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics
NCT05722275Gastric Cancer, Peritoneal Metastases
Chinese Academy of Sciences
Observational
400
Beijing, Fuzhou, Guangzhou, Guiyang, Kunming, Taiyuan, Zhengzhou, Zhenjiang
2023-01-01
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3
324
Guangzhou
2023-01-01
Recruiting
Zhujiang Hospital
Observational
1,000
Guangzhou
2023-01-01
Recruiting
Zhujiang Hospital
Observational
200
Guangzhou
2023-01-01
Recruiting
Sixth Affiliated Hospital, Sun Yat-sen University
Observational
150
Foshan, Guangzhou, Shenzhen
2023-01-01
Recruiting
Screening and Therapeutic Monitoring of Multiple Myeloma by MALDI-TOF MS Analysis
NCT05686447Monoclonal Gammopathies, Multiple Myeloma, M-protein
Zhujiang Hospital
Observational
200
Guangzhou
2023-01-01
Recruiting
Guangzhou Institute of Respiratory Disease
Observational
60
Guangzhou
2023-01-01
Recruiting
Leflunomide for Henoch-Schonlein Purpura
NCT05937880Henoch-Schonlein Purpura
DrugLeflunomide
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
36
Guangzhou
2023-01-01
Active, closed
Novartis Pharmaceuticals
Phase 3
90
Guangzhou, Hangzhou, Dalian, Tianjin
2022-12-30
Recruiting
Erector Spinae Plane Block Improves Organ Dysfunction in Septic Patients With Acute Gastrointestinal Injury
NCT05623722Sepsis, Acute Gastrointestinal Injury, Organ Dysfunction Syndrome
Jing Cai, MD
Not applicable
116
Guangzhou
2022-12-29
Recruiting
Broadenbio Ltd., Co.
Phase 1
78
Guangzhou, Zhengzhou
2022-12-29
Active, closed
AstraZeneca
Phase 3
1,350
Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hefei, Jinan, Kunming
2022-12-29
Recruiting
Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors
NCT05745623Advanced Solid Tumors Harboring NTRK Fusion, Primary Central Nervous System Tumors Harboring NTRK Fusion
DrugICP-723
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1/2
70
Guangzhou
2022-12-27
Recruiting
Anthos Therapeutics, Inc.
Phase 3
2,500
Beijing, Lanzhou, Guangzhou, Shantou, Nanning, Shijiazhuang, Wuhan, Changchun
2022-12-27
Active, closed
AriBio Co., Ltd.
Phase 3
1,535
Beijing, Changchun, Changsha, Chongqing, Guangzhou, Hefei, Heping, Nanchang
2022-12-23
Active, closed
First in Human Study of AZD9592 in Solid Tumors
NCT05647122Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms
DrugsAZD9592·Osimertinib·Leucovorin·Adrucil
AstraZeneca
Phase 1
190
Beijing, Chongqing, Guangzhou, Wuhan
2022-12-21
Active, closed
Amgen
Observational
7,000
Beijing, Chongqing, Dongguan, Foshan, Guangzhou, Huizhou, Zhuhai, Guilin
2022-12-19
Active, closed
Novartis Pharmaceuticals
Phase 3
20
Chongqing, Guangzhou, Chengdu, Beijing
2022-12-19
Active, closed
Janssen Research & Development, LLC
Phase 3
214
Beijing, Changchun, Chengdu, Fuzhou, Guangzhou, Hangzhou, Shanghai, Suzhou
2022-12-15
Active, closed
Amgen
Phase 3
7,297
Beijing, Guangzhou, Huizhou, Nanning, Daqing, Harbin, Nanyang, Wuhan
2022-12-14
Recruiting
AstraZeneca
Phase 3
3,527
Anyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuyang, Guangzhou
2022-12-13
Active, closed
Dizal Pharmaceuticals
Phase 3
324
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin
2022-12-13
Active, closed
Janssen Research & Development, LLC
Phase 1/2
57
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Huizhou, Shanghai, Shenyang
2022-12-13
Active, closed
Pei-Rong Ding
Phase 2
66
Guangzhou
2022-12-12
Active, closed
Sun Yat-sen University
Phase 2
32
Guangzhou
2022-12-12
Recruiting
Pfizer
Phase 3
100
Beijing, Guangzhou, Guiyang, Wuhan, Nanchang, Tianjin
2022-12-09
Active, closed
Bristol-Myers Squibb
Phase 2
189
Guangzhou, Foshan, Maoming Shi, Shenzhen Shi, Liuzhou, Nanning, Haikou, Kunming
2022-12-09
Active, closed
Novartis Pharmaceuticals
Phase 3
696
Guangzhou, Wuhan, Wuxi, Changchun, Chengdu, Hangzhou, Beijing, Shanghai
2022-12-09
Recruiting
Zhongshan Ophthalmic Center, Sun Yat-sen University
Observational
604
Guangzhou
2022-12-05
Active, closed
Zhongshan Ophthalmic Center, Sun Yat-sen University
Not applicable
110
Guangzhou
2022-12-05
Not yet open
Sun Yat-sen University
Not applicable
236
Guangzhou
2022-11-30
Active, closed
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2
321
Guangzhou
2022-11-30
Active, closed
AstraZeneca
Phase 3
1,174
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou
2022-11-28
Active, closed
Sun Yat-sen University
Phase 2
41
Guangzhou
2022-11-25
Active, closed
Sanofi
Phase 2
187
Guangzhou, Hangzhou, Hefei, Nanchang, Nanjing, Shanghai, Shenyang
2022-11-25
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
566
Guangzhou
2022-11-23
Active, closed
Compression Therapy as a Prophylactic Method Against CIPN: a Prospective Self-controlled Trial
NCT05531916Nasopharyngeal Carcinoma, CIPN - Chemotherapy-Induced Peripheral Neuropathy
Sun Yat-sen University
Not applicable
182
Guangzhou
2022-11-21
Recruiting
Hoffmann-La Roche
Phase 1/2
65
Chengdu, Guangzhou, Nanning
2022-11-16
Recruiting
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2
70
Hefei, Beijing, Fujian, Fuzhou, Foshan, Guangzhou, Shijiazhuang, Harbin
2022-11-15
Recruiting
Janssen Research & Development, LLC
Phase 2
520
Baoding, Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Huizhou
2022-11-11
Recruiting
Pfizer
Phase 3
1,060
Beijing, Fuzhou, Guangzhou, Wuhan, Nanjing, Suzhou, Changchun, Shanghai
2022-11-10
Active, closed
AstraZeneca
Phase 3
368
Beijing, Guangzhou, Hangzhou, Nanjing, Shanghai, Shenyang, Tianjin, Wuhan
2022-11-10
Active, closed
Phase II Study of Hemay005 in Patients With Active Ulcerative Colitis
NCT05486104Moderate to Severe Ulcerative Colitis
DrugMufemilast
Ganzhou Hemay Pharmaceutical Co., Ltd
Phase 2
92
Hefei, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanchang, Shenyang
2022-11-08
Active, closed
Bioray Laboratories
Phase 1/2
39
Guangzhou, Guanzhou, Shenzhen, Nanning, Changsha, Tianjin
2022-11-02
Recruiting
Second Affiliated Hospital of Guangzhou Medical University
Phase 3
187
Guangzhou
2022-11-02
Recruiting
PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)
NCT05357846Squamous Cell Esophageal Carcinoma, Esophageal Cancer, Oesophageal Cancer
DrugsTaxol·Sintilimab·Paclitaxel·Cisplatin
Sun Yat-sen University
Phase 3
422
Guangzhou
2022-11-01
Recruiting
Zhongshan Ophthalmic Center, Sun Yat-sen University
Observational
600
Guangzhou
2022-11-01
Recruiting
MSD R&D (China) Co., Ltd.
Phase 1/2
203
Chongqing, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan, Xuzhou, Chengdu
2022-11-01
Recruiting
Henan Genuine Biotech Co., Ltd.
Phase 1/2
153
Beijing, Guangzhou, Zhengzhou
2022-10-31
Recruiting
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1
470
Hefei, Wuhu, Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha
2022-10-26
Active, closed
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
NCT05544929Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma, Carcinoma, Renal Cell, Carcinoma, Ovarian Epithelial
DrugsKeytruda·Pembrolizumab
Novartis Pharmaceuticals
Phase 1
126
Guangzhou, Beijing
2022-10-26
Active, closed
Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT05479994Leukemia, Lymphoma, Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma
DrugSonrotoclax
BeiGene
Phase 2
100
Hefei, Beijing, Fuzhou, Quanzhou, Zhangzhou, Lanzhou, Guangzhou, Shaoguan
2022-10-25
Recruiting
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
400
Fuzhou, Lanzhou, Guangzhou, Meizhou, Haikou, Chengde, Tangshan, Harbin
2022-10-24
Recruiting
Zhujiang Hospital
Observational
10,000
Guangzhou
2022-10-19
Active, closed
Bristol-Myers Squibb
Phase 2
94
Maoming, Shenzhen, Liuzhou, Nanning, Haikou, Kunming, Guangzhou
2022-10-17
Not yet open
Effect of Prebiotics on Blood Pressure Management
NCT05364736Hypertension, Gastrointestinal Microbiome
Sun Yat-sen University
Not applicable
100
Guangzhou
2022-10-17
Active, closed
Janssen Research & Development, LLC
Phase 3
864
Beijing, Changchun, Changsha, Chaoyang District, Chengdu, Fuzhou, Guangzhou, Hangzhou
2022-10-13
Active, closed
Gilead Sciences
Phase 3
1,021
Chengdu, Chongqing, Deyang, Fuzhou, Guangzhou, Hangzhou, Jiangxi, Jinan
2022-10-12
Active, closed
Bayer
Phase 1
129
Guangzhou, Changchun, Linyi
2022-10-11
Active, closed
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
NCT05508789Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases
DrugDonanemab
Eli Lilly and Company
Phase 3
1,500
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou Fujian, Guangzhou, Haidian District
2022-10-10
Recruiting
Sun Yat-sen University
Observational
800
Fuzhou, Dongguan, Foshan, Guangzhou, Shantou, Shaoguan, Shenzhen, Zhongshan
2022-10-10
Recruiting
Peking Union Medical College Hospital
Observational
2,000
Beijing, Fuzhou, Guangzhou, Shenzhen, Nanning, Hohhot, Nanjing, Nanchang
2022-10-01
Active, closed
Hutchmed
Phase 2/3
111
Fuyang, Fuzhou, Lanzhou, Guangzhou, Shenzhen, Zhanjiang, Guilin, Haikou
2022-09-30
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 4
210
Guangzhou
2022-09-27
Recruiting
Janssen Research & Development, LLC
Phase 2/3
201
Beijing, Changchun, Changsha, Chengdu, Chifeng, Fuzhou, Guangzhou, Jinan
2022-09-23
Recruiting
Celgene
Phase 3
810
Beijing, Chongqing, Xiamen, Guangzhou, Shenzhen, Liuzhou, Nanning, Shijiazhuang
2022-09-20
Active, closed
Genmab
Phase 3
549
Beijing, Fuzhou, Xiamen, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Changsha
2022-09-20
Active, closed
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 2
381
Baotou, Beijing, Changchun, Guangzhou, Haikou, Luoyang, Nanchang, Nanjing
2022-09-16
Active, closed
AstraZeneca
Phase 3
594
Baoding, Beijing, Changsha, Chengdu, Deyang, Guangzhou, Hangzhou, Hefei
2022-09-15
Recruiting
Nanfang Hospital, Southern Medical University
Not applicable
278
Guangzhou
2022-09-15
Active, closed
Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002)
NCT05520619Esophageal Squamous Cell Carcinoma, Locally Advanced Esophageal Squamous Cell Carcinoma
DrugsPaclitaxel, Cisplatin·Taxol·Tislelizumab
Sun Yat-sen University
Phase 2
114
Guangzhou
2022-09-15
Active, closed
Biogen
Phase 2/3
450
Beijing, Chongqing, Fuzhou, Dongguan, Guangzhou, Shenzhen, Zhongshan, Nanyang
2022-09-13
Active, closed
Janssen Research & Development, LLC
Phase 3
418
Beijing, Chengdu, Chongqing, Ganzhou, Guangzhou, Hangzhou, Hefei, Jinhua
2022-09-13
Recruiting
Guangdong Association of Clinical Trials
Phase 2
180
Beijing, Chongqing, Foshan, Fuzhou, Guangzhou, Guanzhou, Hangzhou, Hefei
2022-09-13
Active, closed
Canwell Biotech Limited
Phase 1
27
Guangzhou
2022-09-09
Active, closed
GlaxoSmithKline
Phase 3
110
Beijing, Changsha, Guangzhou, Nanchang, Shanghai, Suzhou, Wuhan
2022-09-06
Recruiting
AstraZeneca
Phase 2
454
Changsha, Chongqing, Guangzhou, Hangzhou, Hefei, Shanghai, Shenyang, Wuhan
2022-09-06
Active, closed
Study of Sonrotoclax (BGB-11417) Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma
NCT05471843Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma (MCL), Relapsed Mantle Cell Lymphoma
DrugSonrotoclax
BeOne Medicines
Phase 1/2
125
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Haikou, Zhengzhou, Wuhan
2022-09-05
Recruiting
Nanfang Hospital, Southern Medical University
Phase 2
100
Guangzhou
2022-09-02
Recruiting
Nanfang Hospital, Southern Medical University
Not applicable
344
Quanzhou, Guangzhou, Shantou, Ganzhou, Changsha, Hengyang, Changchun, Shenyang
2022-09-01
Recruiting
Teligene US
Phase 2
128
Bengbu, Beijing, Chongqing, Guangzhou, Harbin, Zhengzhou, Wuhan, Changsha
2022-09-01
Recruiting
Pipeline Embolization for Intracranial Aneurysms
NCT06446778Efficacy, Self, Hemodynamic Instability, Stenosis, Aneurysm, Intracranial
Zhujiang Hospital
Observational
1,000
Guangzhou
2022-09-01
Recruiting
A Study on the Correlation Between Cotinine Levels and Aneurysm Wall Enhancement on HRMRI.
NCT06447714Cotinine Levels, Arterial Aneurysm Wall Enhancement on HRMRI
Zhujiang Hospital
Observational
450
Guangzhou
2022-09-01
Active, closed
Sinotau Pharmaceutical Group
Phase 3
196
Beijing, Fuzhou, Xiamen, Guangzhou, Zhengzhou, Wuhan, Nanjing, Changchun
2022-08-31
Recruiting
Asciminib Roll-over Study
NCT04877522Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
DrugsAsciminib single agent·Bosutinib·ABL001·Nilotinib
Novartis Pharmaceuticals
Phase 4
347
Chongqing, Guangzhou, Zhengzhou, Wuhan, Changchun, Xian, Chengdu, Beijing
2022-08-30
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
153
Beijing, Chongqing, Nanning, Guangzhou, Harbin, Zhengzhou, Changsha, Nanjing
2022-08-23
Active, closed
Sanofi
Phase 2/3
1,856
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Nanchang
2022-08-22
Recruiting
The Cohort Study of Pediatric Cataract
NCT05472844Pediatric Cataract
Zhongshan Ophthalmic Center, Sun Yat-sen University
Observational
5,000
Guangzhou
2022-08-22
Active, closed
Bristol-Myers Squibb
Phase 2
34
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Shijiazhuang, Xuzhou, Shenyang
2022-08-19
Active, closed
Janssen Research & Development, LLC
Phase 1
167
Chongqing, Guangzhou, Tianjin, Wuhan
2022-08-18
Active, closed
Nanfang Hospital, Southern Medical University
Phase 2
48
Guangzhou
2022-08-18
Active, closed
Sun Yat-sen University
Phase 2
105
Guangzhou
2022-08-17
Recruiting
Efficacy and Safety of ALSS Treatment for ICIs-LF in Patients With HCC
NCT05484908Immune-Mediated Hepatitis, Liver Failure, Hepatocellular Carcinoma
Third Affiliated Hospital, Sun Yat-Sen University
Not applicable
60
Guangzhou
2022-08-12
Recruiting
International Study of Cerebral Oxygenation and Electrical Activity During Major Neonatal Surgery
NCT05673499Congenital Disorders, Cerebral Desaturation, Neonatal Surgery
Children's Hospital of Philadelphia
Observational
900
Guangzhou, Shanghai, Shenyang, Sichuan
2022-08-12
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
36
Guangzhou, Shanghai
2022-08-11
Active, closed
Novo Nordisk A/S
Phase 3
412
Beijing, Guangzhou, Liuzhou, Sanya, Zhengzhou, Wuhan, Changsha, Changchun
2022-08-10
Active, closed
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
255
Guangzhou
2022-08-07
Active, closed
Janssen Research & Development, LLC
Phase 3
418
Beijing, Changchun, Changzhou, Chengdu, Chongqing, Ganzhou, Guangzhou, Hangzhou
2022-08-05
Active, closed
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
381
Guangzhou
2022-08-04
Active, closed
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
NCT05489237Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumor (GIST), Digestive System Disease, Gastrointestinal Diseases
DrugIDRX-42
IDRX, Inc., a wholly owned subsidiary of GSK, LLC
Phase 1
276
Beijing, Guangzhou, Wuhan
2022-08-03
Recruiting
D3 Bio (Wuxi) Co., Ltd
Phase 1/2
442
Hefei, Beijing, Guangzhou, Hangzhou, Harbin, Wuhan, Changsha, Zhengzhou
2022-08-03
Recruiting
Nanfang Hospital, Southern Medical University
Not applicable
300
Guangzhou
2022-08-01
Active, closed
Sun Yat-sen University
Phase 2
47
Guangzhou
2022-08-01
Recruiting
China HEalthy Aging and Dementia Study (HEAD)
NCT07912710Alzheimer Disease (AD), Mild Cognitive Impairment (MCI), Dementia, Vascular Dementia (VaD)
Fudan University
Observational
20,000
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hefei, Jinan
2022-08-01
Recruiting
Immune Indicator Model for Predicting Efficacy of PD-1 Monoclonal Antibody
NCT05392413Esophageal Squamous Cell Carcinoma, PD-1 Inhibitor
Nanfang Hospital, Southern Medical University
Observational
200
Guangzhou
2022-08-01
Not yet open
Effects of Non-surgical Periodontal Therapy on Cardiovascular Risk
NCT05459727Cardiovascular Diseases, Periodontitis
Nanfang Hospital, Southern Medical University
Not applicable
376
Guangzhou
2022-08-01
Recruiting
Guangdong Association of Clinical Trials
Observational
180
Foshan, Guangzhou, Shantou, Zhongshan
2022-08-01
Active, closed
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
132
Guangzhou
2022-08-01
Not yet open
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
64
Guangzhou
2022-08
Recruiting
Sun Yat-sen University
Phase 2
194
Guangzhou
2022-07-29
Active, closed
AstraZeneca
Phase 4
43
Beijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2022-07-29
Recruiting
Janssen Research & Development, LLC
Phase 1/2
225
Dalian, Guangzhou, Hangzhou, Wuhan
2022-07-29
Active, closed
Merck Sharp & Dohme LLC
Phase 3
251
Beijing, Chongqing, Guangzhou, Zhengzhou, Wuhan, Nanjing, Suzhou, Nanchang
2022-07-27
Active, closed
Shanghai Junshi Bioscience Co., Ltd.
Phase 1
133
Chizhou, Fuzhou, Wuwei, Guangzhou, Meizhou, Shijiazhuang, Wuhan, Harbin
2022-07-26
Recruiting
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT05254743Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma
DrugsPirtobrutinib·Ibrutinib
Loxo Oncology, Inc.
Phase 3
737
Changsha, Guangzhou, Haikou, Hangzhou, Hefei, Nanchang, Nanning, Shanghai
2022-07-22
Active, closed
Janssen Research & Development, LLC
Phase 2
703
Beijing, Changsha, Changzhou, Chengdu, Chongqing, Foshan, Guangzhou, Haikou
2022-07-22
Active, closed
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
NCT05458297Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
DrugsNemtabrutinib·Zilovertamab vedotin
Merck Sharp & Dohme LLC
Phase 2
189
Beijing, Guangzhou, Zhengzhou, Wuhan, Suzhou, Xuzhou, Nanchang, Chuangchun
2022-07-21
Active, closed
Gilead Sciences
Phase 3
623
Beijing, Changsha, Chengdu, Chongqing, Deyang, Guangzhou, Hangzhou, Harbin
2022-07-20
Active, closed
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
206
Fuzhou, Xiamen, Lanzhou, Guangzhou, Yulin, Zhengzhou, Changsha, Nanchang
2022-07-20
Active, closed
DualityBio Inc.
Phase 1/2
1,123
Bengbu, Hefei, Fuzhou, Lanzhou, Dongguan, Guangzhou, Guigang, Nanning
2022-07-19
Active, closed
Sun Yat-sen University
Phase 2
84
Guangzhou
2022-07-15
Active, closed
GlaxoSmithKline
Phase 3
163
Beijing, Guangzhou, Hefei, Nanjing, Qingdao, Shanghai, Shenzhen, Wenzhou
2022-07-14
Active, closed
Novartis Pharmaceuticals
Phase 3
452
Guangzhou, Shantou, Shenzhen, Liuzhou, Haikou, Wuhan, Changsha, Nanjing
2022-07-14
Active, closed
INSPIRIS China PMCF Study
NCT05404880Aortic Valve Replacement
Edwards Lifesciences
Observational
255
Beijing, Xiamen, Guangzhou, Shenzhen, Zhengzhou, Nanjing, Xi'an, Chengdu
2022-07-13
Active, closed
AstraZeneca
Phase 2
72
Baoding, Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou
2022-07-13
Recruiting
Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer
NCT05200260Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
DrugsOlaparib·Bevacizumab
Shanghai Gynecologic Oncology Group
Phase 2
220
Foshan, Guangzhou, Hangzhou, Hefei, Shanghai
2022-07-13
Active, closed
AstraZeneca
Phase 1/2
119
Beijing, Bengbu, Changchun, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou
2022-07-11
Recruiting
Sun Yat-sen University
Observational
11,625
Guangzhou
2022-07-10
Recruiting
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA
NCT05461664Gastrointestinal Stromal Tumors, Unresectable Solid Tumor, Recurrent Metastatic Malignant Neoplasm
Xinhua Zhang, MD
Observational
74
Guangzhou
2022-07-10
Recruiting
A Multicenter Study of Avapritinib Efficacy and Safety of Metastatic or Unresectable Gastrointestinal Stromal Tumors
NCT05464875Gastrointestinal Stromal Tumors, Unresectable Solid Tumor, Recurrent Metastatic Malignant Neoplasm
Xinhua Zhang, MD
Observational
74
Guangzhou
2022-07-09
Active, closed
Daiichi Sankyo
Phase 3
586
Beijing, Changchun, Changsha, Chengdu, Chibi, Fuzhou, Guangzhou, Haidian
2022-07-08
Active, closed
Pfizer
Phase 2
35
Hefei, Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Changchun, Shenyang
2022-07-07
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
635
Guangzhou
2022-07-06
Recruiting
Sun Yat-sen University
Phase 3
766
Chongqing, Guangzhou, Hengyang, Shenyang, Xi'an, Nanchong
2022-07-05
Recruiting
Nanfang Hospital, Southern Medical University
Observational
20,000
Guangzhou
2022-07-01
Active, closed
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
432
Bengbu, Wuhu, Beijing, Chongqing, Fuzhou, Lanzhou, Wuwei, Guangzhou
2022-07-01
Recruiting
Lepu Biopharma Co., Ltd.
Phase 1/2
18
Guangzhou, Changsha
2022-06-30
Active, closed
BioDlink Biopharm Co., Ltd.
Phase 3
488
Hefei, Beijing, Jilin City, Chongqing, Fuzhou, Guangzhou, Shantou, Shenzhen
2022-06-28
Active, closed
A Phase II Study of AK104 Plus Lenvatinib and TACE in HCC
NCT05319431Unresectable, Non-metastatic Hepatocellular Carcinoma
DrugsCadonilimab·Lenvatinib
Akeso
Phase 2
60
Beijing, Guangzhou, Zhengzhou, Changsha, Jinan
2022-06-28
Recruiting
Sixth Affiliated Hospital, Sun Yat-sen University
Observational
1,700
Guangzhou, Zhuhai
2022-06-24
Active, closed
Sanofi
Phase 3
531
Beijing, Changsha, Guangzhou, Hangzhou, Nanchang, Nanning, Qingdao, Shenyang
2022-06-23
Active, closed
Sun Yat-sen University
Phase 1/2
46
Beijing, Dalian, Guangzhou, Nanchang
2022-06-23
Recruiting
Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer
NCT05430399Breast Neoplasms, Locally Advanced or Metastatic Breast Cancer
DrugsUtidelone·Docetaxel
Sun Yat-sen University
Phase 3
349
Guangzhou, Hunan
2022-06-21
Active, closed
Singlera Genomics Inc.
Observational
800
Beijing, Chengdu, Guangzhou, Haerbin, Shanghai, Shenzhen, Taiyuan
2022-06-20
Active, closed
Guangdong Association of Clinical Trials
Phase 3
192
Guangzhou
2022-06-20
Active, closed
Efficacy of Triple-Combination Therapy in Severe PAH-CHD
NCT06196801Congenital Heart Disease, Pulmonary Arterial Hypertension
Guangdong Provincial People's Hospital
Observational
80
Guangzhou
2022-06-17
Recruiting
Guangzhou University of Traditional Chinese Medicine
Not applicable
82
Guangzhou
2022-06-15
Recruiting
Adagene Inc
Phase 1/2
186
Fuzhou, Guangzhou, Hong Kong
2022-06-15
By invitation
Biogen
Phase 3
864
Beijing, Dongguan, Guangzhou, Shenzhen, Zhongshan, Haikou, Shijiazhuang, Changsha
2022-06-10
Active, closed
Merck Sharp & Dohme LLC
Phase 1
12
Guangzhou, Zhengzhou, Changsha, Tianjin
2022-06-09
Recruiting
Envafolimab Plus Chemoradiotherapy for Locally Advanced NPC, a Prospective, Single Armed Phase II Trial.
NCT05397769Locally Advanced Nasopharyngeal Carcinoma, Envafolimab, Induction Chemotherapy, PD-L1
DrugEnvafolimab
Sun Yat-sen University
Phase 2
36
Guangzhou
2022-06-08
Recruiting
Astellas Pharma Global Development, Inc.
Phase 1
398
Guangzhou, Zhengzhou, Wuhan, Shanghai, Hangzhou
2022-06-07
Recruiting
Antengene Therapeutics Limited
Phase 1
98
Chongqing, Guangzhou
2022-06-07
Recruiting
The Dampness Syndrome of Chinese Medicine Cohort Study
NCT05315895Chronic Disease, Cancer, Dementia Alzheimers, Metabolic Disease
Guangzhou University of Traditional Chinese Medicine
Observational
100,000
Guangzhou
2022-06-06
Active, closed
Pierre Fabre Medicament
Phase 2
63
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou
2022-06-02
Recruiting
Zhujiang Hospital
Observational
40
Guangzhou
2022-06-01
Active, closed
A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors or Other Solid Tumors
NCT05385692Locally Advanced or Metastatic Digestive Tract Tumors, Solid Tumor
DrugBL-M02D1
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
22
Guangzhou
2022-06-01
Recruiting
CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors
NCT05410717Stage IV Ovarian Cancer, Testis Cancer, Refractory, Endometrial Cancer Recurrent, CAR NK
Second Affiliated Hospital of Guangzhou Medical University
Phase 1
200
Guangzhou
2022-06-01
Recruiting
Sun Yat-sen University
Observational
500
Guangzhou
2022-06-01
Recruiting
Sun Yat-sen University
Not applicable
264
Guangzhou
2022-06-01
Not yet open
Umbrella Biomarker-Guided Therapy in NPC
NCT04605562Nasopharyngeal Carcinoma
DrugsGalunisertib·Palbociclib
Sun Yat-sen University
Phase 2
206
Guangzhou
2022-06
Recruiting
Dimerix Bioscience Pty Ltd
Phase 3
286
Baotou, Beijing, Chengdu, Guangzhou, Hangzhou, Hohhot, Jinan, Nanchang
2022-05-30
Active, closed
A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer
NCT05297890Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
DrugLorlatinib
CStone Pharmaceuticals
Phase 2
70
Guangzhou, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Hangzhou
2022-05-27
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
312
Guangzhou, Zhengzhou
2022-05-25
Recruiting
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2
110
Guangzhou
2022-05-20
Recruiting
Research on Potential Biomarkers of Prediabetes and Diabetes Based on MALDI-TOF MS Platform.
NCT06097065Prediabetes, Diabetes Mellitus, Gestational Diabetes Mellitus, Proteomics
Zhujiang Hospital
Observational
2,860
Guangzhou
2022-05-20
Recruiting
Multicenter Study of Fulminant Type 1 Diabetes in China
NCT05593081Diabetes Mellitus, Type 1
Second Xiangya Hospital of Central South University
Observational
240
Quanzhou, Guangzhou, Nanning, Zunyi, Haikou, Changsha, Yancheng, Nanchang
2022-05-20
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
82
Bengbu, Guangzhou, Guilin, Wuhan, Yueyang, Changchun, Hangzhou
2022-05-20
Active, closed
Sun Yat-sen University
Phase 2
150
Guangzhou
2022-05-17
Active, closed
Shanghai Henlius Biotech
Phase 3
511
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Shenzhen, Guilin
2022-05-17
Active, closed
AstraZeneca
Phase 3
644
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou
2022-05-16
Active, closed
Sun Yat-sen University
Phase 3
452
Guangzhou
2022-05-11
Recruiting
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
NCT05294731B-cell Malignancy, Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
DrugTacabrutideg
BeOne Medicines
Phase 1/2
146
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Nanyang
2022-05-06
Recruiting
Ying Lin
Phase 2
66
Guangzhou
2022-05-06
Recruiting
Sun Yat-sen University
Phase 2
280
Changchun, Chengdu, Dongguan, Dongyang, Foshan, Guangzhou, Hangzhou, Jiangmen
2022-05-06
Recruiting
Phase I Study of JYP0322 in ROS1 Fusion-Positive Solid Tumors
NCT06128148Protein Kinase Inhibitors, Other Protocol Specified Criteria, Lung Neoplasms, Brain Neoplasms
Guangzhou JOYO Pharma Co., Ltd
Phase 1
101
Guangzhou
2022-05-04
Active, closed
Sanofi
Phase 3
104
Beijing, Chengdu, Guangzhou, Shanghai
2022-05-03
Recruiting
EGFR/B7H3 CAR-T on Lung Cancer and Triple Negative Breast Cancer
NCT05341492EGFR/ B7H3-positive Advanced Lung Cancer, EGFR/ B7H3-positive Advanced Triple-negative Breast Cancer
Second Affiliated Hospital of Guangzhou Medical University
Early Phase 1
30
Guangzhou
2022-05-01
Recruiting
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2
17
Guangzhou
2022-05-01
Recruiting
Nanfang Hospital, Southern Medical University
Not applicable
144
Guangzhou
2022-05-01
Recruiting
Shanghai Zhongshan Hospital
Observational
6,000
Xiamen, Guangzhou, Zhengzhou, Wuhan, Jiangyin, Wuxi, Yangzhou, Yixing
2022-05-01
Recruiting
Sun Yat-sen University
Observational
200
Guangzhou
2022-04-25
Active, closed
Hoffmann-La Roche
Phase 3
208
Chengdu, Fuzhou, Guangzhou, Tianjin, Wuhan, Zhengzhou
2022-04-25
Active, closed
Sun Yat-sen University
Phase 2
46
Guangzhou
2022-04-24
Active, closed
Sanofi
Phase 3
43
Taipei, Beijing, Guangzhou, Shanghai
2022-04-18
Recruiting
Sun Yat-sen University
Phase 3
556
Guangzhou
2022-04-17
Recruiting
Study of BEBT-109 in Subjects With EGFR Exon 20 Insertion Mutations Non-Small Cell Lung Cancer
NCT06706713Non-Small Cell Lung Cancer, EGFR Exon 20 Insertion Mutation
DrugBEBT-109
BeBetter Med Inc
Phase 2
200
Guangzhou, Changsha
2022-04-15
Active, closed
Eli Lilly and Company
Phase 3
925
Bengbu, Hefei, Wuhu, Beijing, Guangzhou, Harbin, Wuhan, Changsha
2022-04-14
Recruiting
Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
NCT05288205KRAS P.G12C, Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma
DrugsJAB-3312·Glecirasib
Allist Pharmaceuticals, Inc.
Phase 1/2
240
Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Shenzhen, Harbin, Zhengzhou
2022-04-14
Recruiting
Chronic Kidney Disease-related Sarcopenia With Poor Prognosis
NCT05353660Chronic Kidney Diseases, Sarcopenia
Nanfang Hospital, Southern Medical University
Observational
1,000
Guangzhou
2022-04-11
By invitation
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 2/3
600
Beijing, Guangzhou, Changsha, Wuxi, Nanchang, Jinan, Chengdu, Yibin
2022-04-05
Active, closed
Merck Sharp & Dohme LLC
Phase 3
100
Beijing, Tianjin, Chongqing, Fuzhou, Guangzhou, Shantou, Nanning, Harbin
2022-04-02
Recruiting
Sun Yat-sen University
Phase 3
212
Guangzhou, Beijing, Chengdu, Fuzhou, Guiyang, Hangzhou, Nanchang, Nanning
2022-04-01
Not yet open
Urinary Continence of Female POPRC and OIN
NCT05325216Urinary Bladder Neoplasms, Woman, Sexual Dysfunction, Physiological, Treatment Outcome
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
58
Guangzhou
2022-04
Recruiting
Zhujiang Hospital
Not applicable
440
Guangzhou
2022-03-29
Recruiting
National Registry and Cohort Study of Pulmonary Vascular Disease
NCT05368467Pulmonary Arterial Hypertension
Nanjing First Hospital, Nanjing Medical University
Observational
1,000
Guangzhou, Nanjing, Tianjin, Beijing, Changsha, Chendu, Shenyang, Wuhan
2022-03-29
Active, closed
AstraZeneca
Phase 3
760
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou
2022-03-28
Active, closed
Pfizer
Phase 3
854
Guangzhou, Tianjin, Wenzhou
2022-03-25
Active, closed
AstraZeneca
Phase 3
1,035
Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Jiaxing
2022-03-25
Recruiting
AbbVie
Phase 3
768
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shantou, Zhanjiang
2022-03-25
Active, closed
Hoffmann-La Roche
Phase 2
58
Beijing, Guangzhou, Hangzhou, Shanghai, Shenyang
2022-03-18
By invitation
Xiamen Amoytop Biotech Co., Ltd.
Not applicable
350
Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Guanzhou, Harbin, Hefei
2022-03-18
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,800
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Zhengzhou, Wuhan
2022-03-15
Active, closed
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
530
Beijing, Xiamen, Guangzhou, Shenzhen, Liuzhou, Nanning, Wuhan, Changsha
2022-03-15
Recruiting
Sun Yat-sen University
Phase 3
280
Guangzhou
2022-03-14
Active, closed
BeOne Medicines
Phase 3
799
Wuhu, Beijing, Chongqing, Fuzhou, Xiamen, Foshan, Guangzhou, Huizhou
2022-03-10
Active, closed
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 4
640
Guangzhou
2022-03-10
Active, closed
Genmab
Phase 1/2
49
Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Suzhou, Xuzhou
2022-03-10
Recruiting
Janssen Research & Development, LLC
Phase 4
295
Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai, Xi'an
2022-03-09
Recruiting
A Prospective Cohort Study On Change of Cognitive Function In Aged-related Hearing Loss With Hearing Aids
NCT05694039Age-related Hearing Loss, Hearing Loss, Sensorineural, Hearing Aid, Cognitive Function Abnormal
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
388
Guangzhou
2022-03-09
Recruiting
Hoffmann-La Roche
Phase 1
332
Beijing, Guangzhou, Nanchang, Tianjin
2022-03-07
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
654
Hefei, Guangzhou, Meizhou, Liuzhou, Nanning, Haikou, Baoding, Zhengzhou
2022-03-07
Recruiting
3D Medicines (Sichuan) Co., Ltd.
Phase 2
108
Beijing, Chongqing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Yueyang
2022-03-04
Recruiting
Zhen-Hai Lu
Phase 2
121
Guangzhou
2022-03-02
Recruiting
Changhai Hospital
Not applicable
150
Beijing, Guangzhou, Wuhan, Xi'an, Shanghai, Chengdu, Hangzhou
2022-03-01
Recruiting
Guangdong Provincial People's Hospital
Not applicable
380
Guangzhou
2022-03-01
Recruiting
Pembrolizumab and Induction Chemotherapy in Locally Advanced HNSCC
NCT05272696Head and Neck Squamous Cell Carcinoma
Guangdong Provincial People's Hospital
Phase 2
86
Guangzhou
2022-03-01
Not yet open
Sun Yat-sen University
Phase 3
512
Guangzhou
2022-03-01
Recruiting
Evaluation of Chronic Liver Disease Condition and Transplant Prognosis Assisted by Eye Biological Parameters
NCT06756009Diagnostic Techniques, Ophthalmological, Liver Transplantation, Liver Cirrhoses
Zhongshan Ophthalmic Center, Sun Yat-sen University
Observational
500
Guangzhou
2022-03-01
Active, closed
Sun Yat-sen University
Phase 2
44
Guangzhou
2022-02-28
Active, closed
AstraZeneca
Phase 3
390
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2022-02-21
Active, closed
Laekna Limited
Phase 3
256
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Foshan, Guangzhou, Zhongshan
2022-02-18
Active, closed
Merck Sharp & Dohme LLC
Phase 3
8,100
Beijing, Chongqing, Lanzhou, Guangzhou, Shenzhen, Liuzhou, Wuhan, Changsha
2022-02-18
Active, closed
Tumor-informed MRD for Non-small Cell Lung Cancer
NCT07596433Non-small Cell Lung Cancer (NSCLC)
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
450
Guangzhou
2022-02-18
Recruiting
Sanofi
Phase 3
284
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Shanghai, Suzhou, Wuhan
2022-02-15
Active, closed
AstraZeneca
Phase 3
363
Beijing, Bengbu, Chengdu, Guangzhou, Haikou, Hangzhou, Jinan, Jining
2022-02-15
Active, closed
International Extranodal Lymphoma Study Group (IELSG)
Phase 2
30
Guangzhou, Shanghai
2022-02-11
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
33
Guangzhou, Guiyang, Shijiazhuang, Wuhan, Shenyang, Shanghai, Yibin
2022-02-09
Active, closed
NewAmsterdam Pharma
Phase 3
9,541
Beijing, Bengbu, Changde, Changzhou, Chifeng, Daqing, Foshan, Guangzhou
2022-02-07
Active, closed
AstraZeneca
Phase 3
1,051
Anyang, Beijing, Changchun, Changsha, Guangzhou, Hangzhou, Hefei, Kunming
2022-02-07
By invitation
UCB Biopharma SRL
Phase 3
300
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Kunming
2022-02-03
Active, closed
Merck Sharp & Dohme LLC
Phase 3
280
Hefei, Beijing, Chongqing, Fulingqu, Fuzhou, Guangzhou, Shantou, Zhanjiang
2022-02-03
Recruiting
DualityBio Inc.
Phase 1/2
796
Bengbu, Hefei, Beijing, Hongcun, Chongqing, Xiamen, Lanzhou, Guangzhou
2022-01-31
Recruiting
Pulmonary Watershed Topographic Map Navigation for Lung Nodule Resection
NCT06404164Pulmonary Function Assessment, Disease Free Survival, NSCLC, Stage I
Guangdong Provincial People's Hospital
Not applicable
3,000
Guangzhou
2022-01-30
By invitation
Guangzhou Institute of Respiratory Disease
Observational
213
Guangzhou
2022-01-30
Active, closed
Shenzhen Core Medical Technology CO.,LTD.
Not applicable
50
Beijing, Fuzhou, Guangzhou, Wuhan, Changsha, Zhengzhou, Nanjing, Suzhou
2022-01-26
Active, closed
Phase 3 Clinical Study of AK112 for NSCLC Patients
NCT05184712Non-Squamous Non-small Cell Lung Cancer
DrugsIvonescimab (SMT112·Ivonescimab
Akeso
Phase 3
322
Guangzhou
2022-01-25
Recruiting
PROfiling Based Endometrial Cancer Adjuvant Therapy
NCT05179447Endometrial Cancer Stage I, Endometrial Cancer Stage II
Women's Hospital School Of Medicine Zhejiang University
Not applicable
590
Wuhan, Jinan, Hangzhou, Beijing, Changsha, Guangzhou, Ningbo, Shanghai
2022-01-24
Active, closed
China S3 PMS: SAPIEN 3 China Post Market Registry Study
NCT05168826Aortic Stenosis, Severe
Edwards Lifesciences
Observational
250
Beijing, Xiamen, Guangzhou, Zhengzhou, Wuhan, Changsha, Shanghai, Xi’an
2022-01-24
Recruiting
SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors
NCT05245058HER2-positive Advanced Solid Tumors
DrugSPH5030
Shanghai Pharmaceuticals Holding Co., Ltd
Early Phase 1
150
Hefei, Beijing, Guangzhou, Nanning, Shijiazhuang, Harbin, Anyang, Zhengzhou
2022-01-21
Active, closed
Sun Yat-sen University
Phase 3
214
Guangzhou
2022-01-17
Active, closed
Sun Yat-sen University
Observational
220
Guangzhou
2022-01-15
Recruiting
Merck Sharp & Dohme LLC
Phase 2/3
290
Beijing, Chongqing, Guangzhou, Luoyang, Zhengzhou, Wuhan, Nanchang, Changchun
2022-01-14
Active, closed
Sun Yat-sen University
Phase 2
51
Guangzhou
2022-01-11
Recruiting
Third Affiliated Hospital, Sun Yat-Sen University
Phase 4
5,000
Guangzhou
2022-01-08
Recruiting
Docetaxel, Oxaliplatin and 5-FU for Gastric Cancer With Inoperable Malignant Bowel Obstruction
NCT04840264Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Peritoneal Carcinomatosis
DrugsFluorouracil·Adrucil·Docetaxel·Oxaliplatin
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2
79
Guangzhou
2022-01-07
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2/3
14
Guangzhou, Guilin, Guangdong
2022-01-06
Recruiting
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2
396
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Guanzhou, Nanning
2022-01-06
Active, closed
AbbVie
Phase 4
44
Beijing, Guangzhou, Shenzhen, Zhengzhou, Wuhan, Xiangyang, Suzhou, Nanchang
2022-01-06
Active, closed
Li Zhang, MD
Phase 2
106
Guangzhou
2022-01-06
Active, closed
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1
176
Chongqicun, Fuzhou, Guangzhou, Changsha, Nanchang, Changchun, Jinan, Xi’an
2022-01-04
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
201
Guangzhou
2022-01-01
Recruiting
Sun Yat-sen University
Observational
200
Guangzhou
2022-01-01
Recruiting
IBD Biomarker Discovery and Validation Platform
NCT07686406Crohn Disease (CD), Ulcerative Colitis (UC), Inflammatory Bowel Diseases (IBD)
Sixth Affiliated Hospital, Sun Yat-sen University
Observational
6,000
Guangzhou
2022-01-01
By invitation
Sun Yat-sen University
Observational
58
Guangzhou
2022-01-01
Recruiting
Sun Yat-sen University
Phase 1
39
Guangzhou
2022-01-01
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
200
Guangzhou
2022-01-01
Recruiting
Sun Yat-sen University
Phase 3
323
Guangzhou
2022-01-01
Active, closed
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3
234
Guangzhou
2022-01-01
Recruiting
Yanhong Deng
Phase 2
51
Guangzhou
2022-01-01
Recruiting
Clinical Trial of BAO-G Technique in Complex Aortic Aneurysm Endovascular Repair (BAO-G-02)
NCT07141251Thoracoabdominal Aortic Aneurysm, Endovascular Repair, Complex Aortic Aneurysms
Peking Union Medical College Hospital
Not applicable
60
Beijing, Chongqing, Guangzhou, Haikou, Zhengzhou, Jining, Shanghai
2022-01-01
Recruiting
Multi-model Image of Doxycycline in TAO
NCT05112211Thyroid Associated Ophthalmopathy
DrugDoxycycline Hyclate
Sun Yat-sen University
Not applicable
20
Guangzhou
2022-01-01
By invitation
Sun Yat-sen University
Observational
855
Guangzhou
2021-12-30
Active, closed
Shanghai Xinzhi BioMed Co., Ltd.
Phase 2/3
32
Hefei, Beijing, Guangzhou, Shenzhen, Tangshan, Zhengzhou, Taiyuan, Tianjin
2021-12-30
Recruiting
Sun Yat-sen University
Phase 2
37
Guangzhou
2021-12-29
Active, closed
Lorlatinib Continuation Study
NCT05144997Non-Small-Cell Lung Cancer, NSCLC
DrugLorlatinib
Pfizer
Phase 4
76
Hefei, Beijing, Fuzhou, Guangzhou, Changsha, Nanjing, Changchun, Hangzhou
2021-12-28
Recruiting
Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL
NCT05147467Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugLisaftoclax
Ascentage Pharma Group Inc.
Phase 2
75
Guangzhou, Haikou, Zhengzhou, Wuhan, Suzhou, Nanchang, Tianjin, Hanzhou
2021-12-28
Active, closed
Crizotinib Continuation Clinical Study
NCT05160922NSCLC, ALCL, IMT
DrugCrizotinib
Pfizer
Phase 4
27
Beijing, Fuzhou, Guangzhou, Changchun, Wuhou District, Hangzhou, Shanghai
2021-12-27
Recruiting
Guangdong Provincial People's Hospital
Observational
90,000
Foshan, Guangzhou, Meizhou, Qingyuan, Zhuhai, Ganzhou
2021-12-27
Active, closed
Eli Lilly and Company
Phase 3
152
Beijing, Fuzhou, Guangzhou, Harbin, Changsha, Changchun, Xi'an, Jinan
2021-12-20
Recruiting
Merck Sharp & Dohme LLC
Phase 1
830
Beijing, Fuzhou, Guangzhou, Wuhan, Changchun, Shanghai, Hangzhou
2021-12-17
Active, closed
Sanofi
Phase 4
1,339
Beijing, Dongguan, Guangzhou, Guiyang, Hebei, Hefei, Nanchang, Nanjing
2021-12-16
Active, closed
Xuhua Tan
Not applicable
186
Guangzhou
2021-12-16
Active, closed
Novartis Pharmaceuticals
Phase 3
1,000
Guangzhou, Zhengzhou, Changsha, Baotou, Hohhot, Nanchang, Changchun, Beijing
2021-12-16
Recruiting
Zhongshan Ophthalmic Center, Sun Yat-sen University
Not applicable
228
Guangzhou
2021-12-14
Active, closed
GlaxoSmithKline
Phase 2
366
Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Kunming, Shanghai
2021-12-14
Active, closed
Regeneron Pharmaceuticals
Phase 3
288
Beijing, Fuzhou, Guangdong, Guangzhou, Shenzhen, Haikou, Wuhan, Changsha
2021-12-14
Active, closed
Merck Sharp & Dohme LLC
Phase 3
643
Hefei, Beijing, Fuzhou, Lanzhou, Guangzhou, Zhanjiang, Nanning, Haikou
2021-12-13
Active, closed
Sun Yat-sen University
Phase 2
47
Guangzhou
2021-12-10
Recruiting
Johnson & Johnson Enterprise Innovation Inc.
Phase 3
500
Bengbu, Changsha, Chengdu, Dongguan, Fuzhou, Guangzhou, Jinan, Linyi
2021-12-10
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
15
Guangzhou
2021-12-10
Active, closed
Green Valley (Shanghai) Pharmaceuticals Co., Ltd.
Phase 4
800
Beijing, Chongqing, Lanzhou, Foshan, Guangzhou, Shenzhen, Guiyang, Baoding
2021-12-07
Recruiting
UCB Biopharma SRL
Phase 3
350
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Kunming
2021-12-07
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
69
Chongqing, Guangzhou, Guilin, Jinan, Taizhou
2021-12-07
Active, closed
Jazz Pharmaceuticals
Phase 3
920
Beijing, Bengbu, Changsha, Changzhi, Changzhou, Chengdu, Fuzhou, Guangzhou
2021-12-02
Recruiting
Guangdong Provincial People's Hospital
Observational
120
Guangzhou
2021-12-01
Recruiting
Sun Yat-sen University
Observational
60
Guangzhou
2021-12-01
Recruiting
Neoadjuvant FOLFOXIRI Versus Immediate Surgery for Stage II and III Colon Cancers
NCT05194878Colon Cancer Stage II, Colon Cancer Stage III
Sun Yat-sen University
Phase 3
840
Guangzhou
2021-12-01
Active, closed
Hoffmann-La Roche
Phase 3
49
Guangzhou, Harbin, Wuhan, Jinan, Hangzhou, Beijing, Changchun, Changsha
2021-12-01
Recruiting
Minocycline for Chronic Autoimmune Uveitis
NCT05474729Minocycline, Uveitis, Retinal Degeneration
DrugMinocycline
Sun Yat-sen University
Phase 1/2
10
Guangzhou
2021-12-01
Recruiting
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor
NCT05194982Locally Advanced or Metastatic Solid Tumor
DrugIza-bren
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
570
Chongqing, Guangzhou, Wuhan, Changsha, Shanghai, Taiyuan
2021-11-29
Active, closed
Womed
Not applicable
160
Guangzhou, Hangzhou, Shanghai
2021-11-29
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
36
Bengbu, Dongguan, Guangzhou, Changsha, Chengdu
2021-11-26
Active, closed
Novartis Pharmaceuticals
Phase 3
17,004
Beijing, Foshan, Guangzhou, Nanning, Harbin, Jingzhou, Wuhan, Changsha
2021-11-23
Active, closed
AstraZeneca
Phase 3
145
Beijing, Guangzhou, Shenyang
2021-11-19
Active, closed
A Study of LP-128 Capsules in Healthy Subjects
NCT05130567Chronic Hepatitis b
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 1
104
Guangzhou
2021-11-19
Active, closed
Pediatric Spinal Muscular Atrophy (SMA) China Registry
NCT05042921Muscular Atrophy, Spinal
Biogen
Observational
600
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shenzhen, Nanning
2021-11-18
Recruiting
Pfizer
Phase 3
245
Guangzhou, Guiyang, Wuhan, Nanchang, Tianjin, Beijing
2021-11-17
Active, closed
Janssen Research & Development, LLC
Phase 3
776
Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Huizhou
2021-11-17
Recruiting
Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
NCT05024214Solid Tumors, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma
DrugsEnvafolimab·Sunitinib·Lenvatinib
3D Medicines (Sichuan) Co., Ltd.
Phase 1/2
170
Bengbu, Beijing, Fuzhou, Xiamen, Dongguan, Guangzhou, Zhuhai, Haerbin
2021-11-15
Recruiting
Guangzhou Concord Cancer Center
Not applicable
80
Guangzhou
2021-11-09
Recruiting
Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors
NCT05187338Lung Cancer, Liver Cancer, Colorectal Cancer, Pancreas Cancer
DrugsIpilimumab·Durvalumab·Pembrolizumab
Second Affiliated Hospital of Guangzhou Medical University
Phase 1/2
100
Guangzhou
2021-11-01
Active, closed
AstraZeneca
Phase 3
454
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan
2021-10-28
Active, closed
Hoffmann-La Roche
Phase 3
478
Beijing, Changchun, Guangzhou, Harbin, Nanchang, Nanjing, Shanghai, Tianjin
2021-10-27
Active, closed
AstraZeneca
Phase 3
927
Beijing, Changsha, Chongqing, Guangzhou, Kunming, Nanning, Qingdao, Shanghai
2021-10-25
Recruiting
AstraZeneca
Phase 1/2
460
Beijing, Changsha, Chongqing, Guangzhou, Kunming, Shandong
2021-10-18
Active, closed
AstraZeneca
Phase 3
732
Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou
2021-10-18
Active, closed
Boehringer Ingelheim
Phase 1
151
Bengbu, Changsha, Fuzhou, Guangzhou, Wuhan
2021-10-18
Active, closed
Janssen Research & Development, LLC
Phase 3
587
Beijing, Changchun, Changshashi, Chaoyang District, Chengdu, Fuzhou, Guangzhou, Hangzhou
2021-10-14
Active, closed
Merck Sharp & Dohme LLC
Phase 1
45
Beijing, Guangzhou, Nanjing, Tianjin, Hangzhou
2021-10-13
Active, closed
Gilead Sciences
Phase 2
53
Beijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Nanjing
2021-10-12
Active, closed
PharmaEssentia
Phase 2
49
Beijing, Changsha, Chongqing, Guangzhou, Hefei, Shanghai, Shenzhen, Suzhou
2021-10-08
Active, closed
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
NCT04971226Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
DrugsBosutinib·Asciminib·ABL001·Nilotinib
Novartis Pharmaceuticals
Phase 3
405
Guangzhou, Shenzhen, Zhengzhou, Wuhan, Nanjing, Suzhou, Xian, Chengdu
2021-10-06
Recruiting
Pfizer
Phase 3
893
Beijing, Fuzhou, Guangzhou, Shenzhen, Shijiazhuang, Zhengzhou, Wuhan, Nanjing
2021-10-04
Active, closed
Eli Lilly and Company
Phase 3
874
Bengbu, Beijing, Fuzhou, Guangzhou, Jiangmen, Shenzhen, Zhanjiang, Zhongshan
2021-10-04
Active, closed
Guangzhou Women and Children's Medical Center
Observational
150
Guangzhou
2021-10-01
Active, closed
Guangzhou Women and Children's Medical Center
Observational
127
Foshan, Guangzhou
2021-10-01
Recruiting
Sun Yat-sen University
Observational
1,000
Guangzhou
2021-10-01
Active, closed
Hoffmann-La Roche
Phase 3
217
Changchun, Changsha, Chengdu, Guangzhou, Harbin, Jining, Nanning, Shanghai
2021-09-30
Active, closed
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
NCT04931654Carcinoma, Non-Small-Cell Lung, Gastric Cancer, Gastroesophageal Junction Cancer
DrugSabestomig
AstraZeneca
Phase 1/2
136
Beijing, Guangzhou
2021-09-28
Active, closed
Loxo Oncology, Inc.
Phase 3
282
Hefei, Beijing, Guangzhou, Wuhan, Changsha, Hohhot, Nanchang, Shenyany
2021-09-23
Recruiting
ICCRT vs. CRT for Locally Advanced Nasopharyngeal Carcinoma
NCT05062005Locally Advanced Nasopharyngeal Carcinoma
First Affiliated Hospital, Sun Yat-Sen University
Phase 3
447
Guangzhou
2021-09-22
Recruiting
Novartis Pharmaceuticals
Phase 3
540
Beijing, Guangzhou, Luoyang, Zhengzhou, Changsha, Changchun, Yinchuan, Taiyuan
2021-09-20
Active, closed
Loxo Oncology, Inc.
Phase 3
600
Beijing, Changsha, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Hengyang
2021-09-20
Recruiting
Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (OOC-002)
NCT05098119Oral Cavity Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma
DrugSintilimab
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
43
Guangzhou
2021-09-16
Recruiting
BeOne Medicines
Phase 1/2
246
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan
2021-09-16
Active, closed
Nanfang Hospital, Southern Medical University
Observational
1,300
Chongqing, Guangzhou, Hebei, Changsha, Nanjing, Xuzhou, Nanchang, Changchun
2021-09-15
Recruiting
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
NCT05006716B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma
DrugTacabrutideg
BeOne Medicines
Phase 1/2
689
Beijing, Guangzhou, Zhengzhou, Yichang, Shanghai, Tianjin, Wenzhou
2021-09-13
Active, closed
AstraZeneca
Phase 3
98
Beijing, Ganzhou, Guangzhou, Jinan, Shenyang, Tianjin, Zhengzhou
2021-09-12
Active, closed
Hutchmed
Phase 3
412
Guangzhou
2021-09-06
Active, closed
Zhigang Li
Phase 3
426
Shanghai, Anyang, Guangzhou, Hefei
2021-09-01
Recruiting
S-1 and Oxaliplatin (SOX) Plus Sintilimab in the Locally Advanced Esophagogastric Junction Adenocarcinoma
NCT04989985Locally Advanced Gastroesophageal Junction Adenocarcinoma, Chemotherapy Effect
DrugsSinitilimab·Teysuno·Oxaliplatin
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2
302
Guangzhou
2021-09-01
Recruiting
Guangdong Provincial People's Hospital
Observational
300
Guangzhou
2021-09-01
Not yet open
Lepu Medical Technology (Beijing) Co., Ltd.
Not applicable
2,150
Bengbu, Hefei, Wuhu, Beijing, Chongqing, Lanzhou, Foshan, Guangzhou
2021-09
Active, closed
Inventiva Pharma
Phase 3
1,000
Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Shenzhen, Nanning
2021-08-19
Recruiting
Sun Yat-sen University
Phase 3
266
Guangzhou
2021-08-16
Active, closed
Akeso
Phase 3
296
Hefei, Fuzhou, Xiamen, Dongguan, Guangzhou, Jiangmen, Shantou, Shenzhen
2021-08-16
Recruiting
Sun Yat-sen University
Phase 2
30
Guangzhou
2021-08-13
Active, closed
Guangdong Provincial People's Hospital
Phase 3
440
Xiamen, Guangzhou, Huizhou, Jiangmen, Shenzhen, Zhanjiang, Nanning, Shangqiu
2021-08-12
Recruiting
Merck Sharp & Dohme LLC
Phase 2
355
Beijing, Guangzhou, Shanghai, Chengdu
2021-08-12
Recruiting
Sun Yat-sen University
Phase 2
32
Guangzhou
2021-08-01
By invitation
Chinese Academy of Medical Sciences
Phase 3
606
Beijing, Changsha, Chendu, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2021-08-01
By invitation
Huashan Hospital
Observational
1,000
Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Wuhan, Nanjing, Suzhou
2021-08-01
Active, closed
Sun Yat-sen University
Phase 3
532
Beijing, Chongqing, Foshan, Guangzhou, Nanning, Guiyang, Wuhan, Changsha
2021-08-01
Active, closed
GlaxoSmithKline
Phase 3
72
Beijing, Changchun, Guangzhou, Hangzhou, Jinan, Nanjing, Shenyang, Suzhou
2021-07-28
Recruiting
Novartis Pharmaceuticals
Phase 3
98
Guangzhou, Wuhan, Beijing, Shanghai
2021-07-28
By invitation
UCB Biopharma SRL
Phase 3
760
Beijing, Changchun, Guangzhou, Guilin, Shanghai, Shantou, Suzhou, Tianjin
2021-07-27
Active, closed
Sun Yat-sen University
Phase 2
150
Bengbu, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Shenzhen, Zhuhai
2021-07-21
Active, closed
Dizal Pharmaceuticals
Phase 2
104
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Haikou, Hangzhou
2021-07-19
Active, closed
Biogen
Phase 3
562
Beijing, Dongguan, Guangzhou, Shenzhen, Haikou, Changsha, Zhuzhou, Wuhan
2021-07-16
Active, closed
Bristol-Myers Squibb
Phase 3
729
Bengbu, Beijing, Guangzhou, Shenzhen, Zhengzhou, Changsha, Changzhou, Nanjing
2021-07-15
Recruiting
Janssen Research & Development, LLC
Phase 3
199
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan
2021-07-15
Active, closed
Bristol-Myers Squibb
Phase 3
670
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Dalian, Shanghai, Yiwu
2021-07-13
Active, closed
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
48
Guangzhou
2021-07-13
Active, closed
Janssen Research & Development, LLC
Phase 1
216
Beijing, Chongqing, Guangzhou, Wenzhou
2021-07-13
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
57
Guangzhou
2021-07-08
Recruiting
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 1
200
Beijing, Guangzhou
2021-07-06
Recruiting
Boehringer Ingelheim
Phase 1
554
Beijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Harbin, Nanning, Shanghai
2021-07-02
Not yet open
Sun Yat-sen University
Phase 2/3
622
Guangzhou
2021-07-01
Active, closed
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1
107
Guangzhou
2021-07-01
Recruiting
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
NCT04900818Solid Tumor, Advanced Cancer, Metastatic Cancer, Gastric Cancer
DrugGivastomig
I-Mab Biopharma US Limited
Phase 1
330
Hefei, Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Shenyang, Shanghai
2021-06-29
Active, closed
Idience Co., Ltd.
Phase 1/2
87
Beijing, Guangzhou, Shanghai
2021-06-28
Active, closed
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
45
Hefei, Guangzhou, Nanning, Shijiazhuang, Zhengzhou, Wuhan, Suzhou, Tianjin
2021-06-25
Active, closed
Hoffmann-La Roche
Phase 3
142
Hangzhou, Beijing, Chengdu, Fuzhou, Guangzhou, Shanghai, Wuhan, Xi'an
2021-06-25
Active, closed
Mirati Therapeutics Inc.
Phase 3
461
Bengbu, Hefei, Beijing, Fuzhou, Guangzhou, Shenzhen, Nanning, Zhengzhou
2021-06-24
Active, closed
AstraZeneca
Phase 3
110
Beijing, Chongqing, Guangzhou, Guizhou, Henan, Hubei, Hunan, Jilin City
2021-06-24
Recruiting
Sun Yat-sen University
Phase 2
100
Guangzhou
2021-06-23
Recruiting
Omics Sequencing of Specimen Derived From Mother-Infant-Pairs
NCT05462366Healthy, Breast-milk Collection, Feces
Zhujiang Hospital
Observational
100
Guangzhou
2021-06-22
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
41
Guangzhou
2021-06-22
Active, closed
Merck Sharp & Dohme LLC
Phase 3
342
Hefei, Beijing, Xiamen, Foshan, Guangzhou, Shenzhen, Nanning, Zhengzhou
2021-06-18
Recruiting
Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer
NCT04790305Carcinoma Breast, Triple-negative Breast Cancer, Invasive Ductal Carcinoma, Breast
DrugHuaier
Fudan University
Phase 4
1,072
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Harbin, Zhengzhou
2021-06-18
Active, closed
Sun Yat-sen University
Phase 2
266
Guangzhou
2021-06-16
Active, closed
Sun Yat-sen University
Phase 1/2
36
Guangzhou
2021-06-16
Active, closed
Novartis Pharmaceuticals
Phase 3
1,144
Nanjing, Xian, Chengdu, Beijing, Guangzhou, Shanghai, Tianjin
2021-06-09
Active, closed
Hangzhou Endonom Medtech Co., Ltd.
Not applicable
88
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Kunming
2021-06-07
Active, closed
Sun Yat-sen University
Observational
231
Guangzhou
2021-06-05
Recruiting
Zhujiang Hospital
Phase 2
41
Guangzhou
2021-06-03
Active, closed
Green Valley (Shanghai) Pharmaceuticals Co., Ltd.
Phase 4
2,500
Hefei, Beijing, Chongqing, Xianmencun, Dongguan, Guangzhou, Shenzhen, Zhuhai
2021-06-02
Recruiting
Sun Yat-sen University
Phase 3
524
Guangzhou
2021-06-01
Recruiting
Sun Yat-sen University
Phase 3
188
Guangzhou
2021-06-01
Recruiting
Xingfei Pan
Observational
200
Guangzhou
2021-06-01
Active, closed
D9319C00001- 1L OC Mono Global RCT
NCT04884360Ovarian Cancer
DrugOlaparib
AstraZeneca
Phase 3
366
Baoji, Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang
2021-05-31
Active, closed
Sun Yat-sen University
Not applicable
124
Guangzhou, Guangdong
2021-05-31
Recruiting
Ascentage Pharma Group Inc.
Phase 1/2
95
Guangzhou, Hangzhou, Shanghai
2021-05-26
Recruiting
Nanfang Hospital, Southern Medical University
Observational
169
Guangzhou
2021-05-25
Recruiting
A Study of BGB-11417 in Participants With Myeloid Malignancies
NCT04771130Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm
DrugsPosaconazole·Sonrotoclax·Azacitidine
BeOne Medicines
Phase 1/2
260
Beijing, Lanzhou, Guangzhou, Shenzhen, Zhengzhou, Wuhan, Suzhou, Nanchang
2021-05-24
Recruiting
Sun Yat-sen University
Phase 2
69
Guangzhou
2021-05-21
Active, closed
Daiichi Sankyo
Phase 3
490
Heifi, Fuzhou, Xiamen, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Changshan
2021-05-21
Recruiting
Janssen Research & Development, LLC
Phase 1/2
420
Beijing, Changchun, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing
2021-05-19
Active, closed
Pfizer
Phase 3
599
Hefei, Beijing, Lanzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing
2021-05-12
Active, closed
Hoffmann-La Roche
Observational
800
Changsha, Guangzhou, Hangzhou, Hefei, Jinan, Nanjing, Nanning, Taiyuan
2021-05-10
Active, closed
AstraZeneca
Phase 3
893
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou
2021-05-10
Recruiting
Sellas Life Sciences Group
Phase 1/2
160
Bengbu, Hefei, Chongqing, Guangzhou, Baoding, Zhengzhou, Suzhou, Nanchang
2021-05-10
Active, closed
Hoffmann-La Roche
Phase 3
1,188
Chengdu, Chongqing, Guangzhou, Harbin, Shanghai, Tianjin, Wuhan, Xi'an
2021-05-04
Not yet open
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
15
Guangzhou
2021-04-30
Active, closed
AstraZeneca
Phase 3
1,157
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Guangzhou, Hangzhou
2021-04-26
Active, closed
Hoffmann-La Roche
Phase 3
557
Changsha, Fuzhou, Guangzhou, Hefei, Nanjing, Shanghai, Shenyang, Tianjin
2021-04-26
Active, closed
Shenzhen TargetRx Co., Ltd.
Phase 1
198
Guangzhou
2021-04-23
Active, closed
Merck Sharp & Dohme LLC
Phase 3
808
Guangzhou, Changsha, Nanjing, Nantong, Shanghai
2021-04-21
Active, closed
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
140
Guangzhou
2021-04-20
Recruiting
Sun Yat-Sen University Cancer Center
Phase 3
228
Guangzhou
2021-04-20
Active, closed
Sun Yat-sen University
Phase 1
40
Guangzhou
2021-04-19
Active, closed
Jia Fan
Phase 3
501
Shanghai, Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei
2021-04-19
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
60
Beijing, Chongqing, Guangzhou, Shenzhen, Xian, Chengdu
2021-04-14
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,688
Bengbu, Beijing, Chongging, Fuzhou, Xiamen, Guangzhou, Harbin, Zhengzhou
2021-04-14
Active, closed
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 3
193
Guangzhou
2021-04-13
Recruiting
HANGZHOU Solution in Bicuspid AS Undergoing TAVR
NCT04722796Aortic Stenosis, Aortic Stenosis With Bicuspid Valve
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
508
Bengbu, Beijing, Fuzhou, Xiamen, Guangzhou, Zhengzhou, Wuhan, Changsha
2021-04-12
Active, closed
Loxo Oncology, Inc.
Phase 3
500
Hefei, Beijing, Fuzhou, Guangzhou, Luoyang, Zhengzhou, Wuhan, Yichang
2021-04-08
Recruiting
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
NCT04728893Hematologic Malignancies, Waldenstroms Macroglobulinaemia, Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia
DrugNemtabrutinib
Merck Sharp & Dohme LLC
Phase 2
490
Hefei, Beijing, Chongqing, Guangzhou, Liuzhou, Nanning, Zhengzhou, Wuhan
2021-04-05
Active, closed
Novo Nordisk A/S
Phase 3
1,205
Beijing, Chongqing, Foshan, Guangzhou, Shenzhen, Shijiazhuang, Changsha, Changzhou
2021-04-01
Recruiting
Sun Yat-sen University
Observational
300
Guangzhou
2021-04-01
Recruiting
The Third Affiliated Hospital of Guangzhou Medical University
Observational
1,200
Guangzhou
2021-04-01
Active, closed
Li Zhang, MD
Phase 3
294
Guangzhou, Zhanjiang
2021-03-29
Recruiting
Boston Scientific Corporation
Observational
5,000
Chaoyang, Xicheng, Chongqing, Guangzhou, Qingdao, Huangpu, Yangpu, Taiyuan
2021-03-29
Active, closed
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
496
Shanghai, Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang
2021-03-18
Active, closed
Hoffmann-La Roche
Phase 3
51
Chengdu, Guangzhou, Tianjin, Wuhan
2021-03-17
Active, closed
Hoffmann-La Roche
Phase 3
746
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Kunming
2021-03-17
Recruiting
MSD R&D (China) Co., Ltd.
Phase 1
100
Beijing, Xiameng, Guangzhou, Shijiazhuang, Zhengzhou, Nanchang, Changchun, Jinan
2021-03-16
Active, closed
Hoffmann-La Roche
Phase 3
342
Anhui, Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2021-03-12
Recruiting
Topotecan and Melphalan for Retinoblastoma
NCT04799002Retinoblastoma, Chemotherapy Effect
DrugsMelphalan·Topotecan
Sun Yat-sen University
Phase 3
50
Guangzhou
2021-03-11
Recruiting
Shanghai Henlius Biotech
Phase 2/3
568
Guangzhou, Hangzhou, Linyi, Shanghai
2021-03-10
Active, closed
Loxo Oncology, Inc.
Phase 3
238
Beijing, Xicheng District, Lanzhou, Guangzhou, Haikou, Zhengzhou, Changsha, Xuzhou
2021-03-09
Recruiting
Sun Yat-sen University
Phase 3
218
Guangzhou, Zhongshan, Nanchang
2021-03-03
Active, closed
Novartis Pharmaceuticals
Phase 3
345
Lanzhou, Foshan, Guangzhou, Shijiazhuang, Baotou, Hohhot, Nanjing, Nantong
2021-03-01
Recruiting
Sun Yat-sen University
Observational
2,000
Guangzhou, Jieyang, Shantou, Shenzhen, Zhanjiang, Zhongshan
2021-03-01
Recruiting
Second Affiliated Hospital of Guangzhou Medical University
Phase 1
50
Guangzhou
2021-03-01
Active, closed
Celgene
Phase 3
313
Guangzhou, Nanyang, Changsha, Nanjing, Nantong, Nanchang, Qingdao, Taiyuan
2021-02-25
Rows per page Showing 2501–3000 of 3345
Previous 4 5 6 7 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 November 2026. https://priyalifescience.com/clinical-trials-china/city/guangzhou?page=6

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 08 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 3,345 of those studies with a site in Guangzhou.

How many clinical trials are recruiting in Guangzhou?

1,977 of the 3,345 studies on this page are recruiting new participants as of the 08 Nov 2026, 03:17 UTC sync. A further 479 have not yet opened recruitment, 820 are active but closed to new participants, and 69 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.